Vir Biotechnology appoints Timothy Coughlin to board
Vir Biotechnology appointed Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. Coughlin, the former CFO of Neurocrine Biosciences, brings extensive experience in finance and operations. He currently serves on the boards of aTyr Pharma, ADC Therapeutics, and Travere Therapeutics.
*this image is generated using AI for illustrative purposes only.
Vir Biotechnology, Inc. has appointed Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. The appointment aims to strengthen the company's governance as it advances its portfolio of therapies for serious infectious diseases and cancer. Coughlin's background in strategic discipline and operational insight is expected to support the company's transition from scientific innovation to commercial therapies.
Marianne De Backer, Chief Executive Officer of Vir Biotechnology, highlighted the value of Coughlin's experience in helping organizations evolve into fully integrated enterprises. His tenure as a chief financial officer and board member spans discovery through commercialization. The company believes his expertise will be crucial as it progresses its treatment regimen for hepatitis delta and its pipeline of masked T-cell engagers for solid tumors.
Coughlin is the former Chief Financial Officer of Neurocrine Biosciences, Inc., where he led the company's transition from a clinical-stage biotechnology firm to a fully integrated commercial pharmaceutical company. He managed the organization through a key regulatory setback, contributing to increased shareholder value. Prior to Neurocrine, he served as Vice President, Financial Services at Catholic Health Initiatives, a nationwide integrated healthcare delivery system. He began his career as a Senior Manager in the Health Sciences practice of Ernst & Young LLP.
Current Board Roles
Timothy Coughlin currently holds the following positions:
| Role | Organization |
|---|---|
| Chair of the Board | aTyr Pharma, Inc. |
| Member of the Board | ADC Therapeutics SA |
| Member of the Board | Travere Therapeutics, Inc. |
He previously served on the boards of Fate Therapeutics, Inc. and Peloton Therapeutics, Inc. prior to its sale to Merck in 2019. Coughlin holds a master's degree in international business from San Diego State University and a bachelor's degree in accounting from Temple University. He is a certified public accountant in California and Pennsylvania.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN dual-masked T-cell engagers for solid tumor indications. The company also maintains a preclinical portfolio across infectious diseases and oncologic malignancies. Vir Biotechnology holds exclusive rights to the universal PRO-XTEN masking platform for oncology and infectious disease, a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
How will Timothy Coughlin's prior experience in navigating regulatory setbacks at Neurocrine Biosciences influence Vir Biotechnology's risk management strategies for its hepatitis delta and oncology programs?
What specific operational milestones does Vir Biotechnology aim to achieve under Coughlin's financial leadership to transition from a clinical-stage to a fully integrated commercial entity?
Could Coughlin's appointment signal potential shifts in Vir Biotechnology's capital allocation strategy, particularly regarding R&D investments versus commercial infrastructure development?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
